Clinical Efficacy Comparison between CHOPE Regimen alone and It Combined with Thalidomide for Relapsed and Refractory Non-Hodgkin's Lymphoma

• Published in: Zhongguo shi yan xue ye xue za zhi Vol. 24; no. 1; p. 84
• Main Author: Yang, Ying-Zi
• Format: Journal Article
• Language: Chinese
• Published: China 01.02.2016
• Subjects: Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cyclophosphamide - therapeutic use; Doxorubicin - therapeutic use; Etoposide - therapeutic use; Humans; Lactate Dehydrogenases - metabolism; Lymphoma, B-Cell - drug therapy; Neoplasm Recurrence, Local; Prednisone - therapeutic use; Survival Rate; Thalidomide - therapeutic use; Treatment Outcome; Vascular Endothelial Growth Factor A - blood; Vincristine - therapeutic use
• ISSN: 1009-2137
• DOI: 10.7534/j.issn.1009-2137.2016.01.016

To investigate the clinical efficacy and safety between CHOPE regimen alone and it combined with thalidomide for relapsed and refractory non-Hodgkin's lymphoma. Eighty patients with relapsed and refractory non-Hodgkin's B cell lymphoma were chosen in our hospital from January 2009 to June 2012, and randomly were divided into 2 groups including the CHOPE regimen group (40 patients) and CHOPE plus thalidomide group (40 patients); and the clinical efficacy, the levels of sVEGF and LDH before and after treatment, the survival rate and the III-IV degree toxic side-effects in these 2 groups were compared. The clinical efficacy of CHOPE+thalidomide group was significant higher than that of CHOPE group alone (P < 0.05). The levels of sVEGF and LDH after treatment in the CHOPE+thalidomide group was significantly higher than that in CHOPE group alone before treatment (P < 0.05). The survival rate in CHOPE+thalidomide group was significant higher than that in CHOPE group alone (P < 0.05). The median survival time in CHO